115576-91-5

Basic information

• Product Name: 1H-Benzimidazole-5-methanol,1-methyl-(9CI)
• Synonyms: 1H-Benzimidazole-5-methanol,1-methyl-(9CI);(1-Methyl-1H-benzo[d]imidazol-5-yl)methanol;(1-Methyl-1H-1,3-benzodiazol-5-yl)Methanol;(1-Methyl-1H-benzo[d]imidazol-5-yl);(1-methyl-1H-benzimidazol-5-yl)methanol
• CAS NO: 115576-91-5
• Molecular Formula: C9H10N2O
• Molecular Weight: 162.191
• Product Categories: BENZIMIDAZOLE
• Mol File: 115576-91-5.mol

Chemical Properties

• Boiling Point: 357.4°C at 760 mmHg
• Flash Point: 170°C
• Appearance: /
• Density: 1.22g/cm³
• Vapor Pressure: 9.92E-06mmHg at 25°C
• Refractive Index: 1.622
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1H-Benzimidazole-5-methanol,1-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole-5-methanol,1-methyl-(9CI)(115576-91-5)
• EPA Substance Registry System: 1H-Benzimidazole-5-methanol,1-methyl-(9CI)(115576-91-5)

Safety Data

• Hazardous Substances Data: 115576-91-5(Hazardous Substances Data)

Usage

Uses

Due to the lack of specific information provided in the materials, the following uses are inferred based on the general properties of benzimidazoles and similar compounds:
Used in Pharmaceutical Industry:
1H-Benzimidazole-5-methanol,1-methyl-(9CI) may be used as an active pharmaceutical ingredient or intermediate for the synthesis of drugs, given its structural features and the diverse applications of benzimidazoles in medicinal chemistry.
Used in Chemical Research:
As a derivative of benzimidazole, 1H-Benzimidazole-5-methanol,1-methyl-(9CI) could be utilized in chemical research for studying the properties and reactions of benzimidazole compounds, contributing to the development of new chemical entities.
Used in Material Science:
1H-Benzimidazole-5-methanol,1-methyl-(9CI) may also find applications in material science, potentially serving as a component in the development of new materials with specific properties, such as conductivity, stability, or reactivity.

InChI:InChI=1/C9H10N2O/c1-11-6-10-8-4-7(5-12)2-3-9(8)11/h2-4,6,12H,5H2,1H3

Upstream product

• 367-80-6 ethyl 4-fluoro-3-nitrobenzoate 
• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 53484-19-8 ethyl 1-methyl-1H-benzo[d]imidazole-5-carboxylate 
• 66315-23-9 ethyl 3-amino-4-(methylamino)benzoate 
• 71254-71-2 ethyl 4-(methylamino)-3-nitrobenzoate 
• 26663-77-4 methyl 1H-benzo[d]imidazole-5-carboxylate 
• 15788-16-6 5-benzimidazolecarboxylic acid 
• 131020-36-5 methyl 1-methyl-1H-benzo[d]imidazole-5-carboxylate 

Downstream Products

• 279226-70-9 1-methyl-1H-benzo[d]imidazole-5-carbaldehyde 

Relevant articles and documents

HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR

A novel heterocyclic compound or a salt thereof useful for selectively inhibiting the degradation of p27Kip1 is provided. The compound or the salt thereof is represented by the following formula (1): wherein A represents an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic group, the group A may have a substituent; the ring B represents a 5- to 8-membered monocyclic heterocyclic ring or a condensed ring containing the monocyclic heterocyclic ring, the ring B may have a substituent; the ring C represents an aromatic ring, the ring C may have a substituent; L represents a linker comprising a main chain having 3 to 5 atoms selected from the group consisting of a carbon atom, a nitrogen atom, an oxygen atom and a sulfur atom, wherein at least one atom in the main chain is a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, the linker L may have a substituent; and n is 0 or 1.

ARYL SUBSTITUTED OLEFINIC COMPOUNDS AS PDE10A INHIBITORS

The present invention provides aryl substituted olefinic compounds as Phosphodiesterase 1 0A (PDE 1 0A) inhibitors. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders by inhibiting Phospho

CALCIUM RECEPTOR MODULATING AGENTS

The compounds of the invention are represented by the following general structure (I) or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.